glp-1 trial results today AstraZeneca's elecoglipron just posted some of the most closely watched Phase IIb data of the year and it landed at the right conference. from the VISTA and SOLSTICE trials, published simultaneously TrimRX | GLP-1 Dose Titration:
Description
KFF Health Tracking Poll May 2024: The Publics Use and Views of GLP-1 Drugs | KFF
Large meta-analyses and pooled data from randomized controlled trials demonstrate that GLP-1 receptor agonists do not increase the risk of depression, anxiety, suicidality, or other serious psychiatric adverse events compared to placebo
From head to toe, GLP-users have noticed these symptoms in specific areas of the body
10.1016/j.physbeh.2020.113039 [DOI] [PMC free article] [PubMed] [Google Scholar] Liu, J
Why should employers care
This includes how to administer GLP-1 injections, how to determine the right dosage, and what to expect in terms of results
